Abstract
Inhibitors of mTOR (mammalian target of rapamycin) are immunosuppressants with less nephrotoxic potential than calcineurin inhibitors and antiproliferative effects, which are advantageous in the case of malignancy. However, a series of adverse events has been reported with the first-generation mTOR inhibitor sirolimus that includes hypersensitivity-like interstitial pneumonitis. To our knowledge, only one case of a pneumonitis associated with everolimus in a heart transplant patient has been reported, and it was related to elevated trough blood levels. We report herein the first case of a kidney graft recipient who developed everolimus-associated pneumonitis with normal trough blood levels that was completely reversed after drug withdrawal. © The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Author supplied keywords
Cite
CITATION STYLE
Alexandru, S., Ortiz, A., Baldovi, S., Milicua, J. M., Ruíz-Escribano, E., Egido, J., & Plaza, J. J. (2008). Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrology Dialysis Transplantation, 23(10), 3353–3355. https://doi.org/10.1093/ndt/gfn401
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.